| Today’s Big NewsMar 21, 2025 |
|
Leverage industry-leading capabilities powered by Kinetic™ to streamline and optimize commercialization activities. Let Syneos Health help increase your probability of market success. .png)
|
|
| By James Waldron Vaxart has laid off 10% of its staff after the U.S. government unexpectedly ordered the biotech stop work on a trial of its COVID-19 vaccine pill. |
|
|
|
By Nick Paul Taylor AstraZeneca has shown its commitment to China amid investigations into its executives and activities, outlining plans to establish a global strategic R&D center in Beijing as part of a $2.5 billion investment in the city. |
By Gabrielle Masson Despite a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about the longevity of the company and evaluating strategic options. |
Sponsored by Syneos Health Dr. Steven O'Day of Agenus discusses the future of cancer immunotherapy on The Top Line podcast. Learn about 'cold' tumors and a potential '2.0 revolution' in immuno-oncology. |
By Darren Incorvaia British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class therapeutics for dementia, the second such fund the venture capitalists have put together. |
By James Waldron MacroGenics has made the final decision to abandon work on one of its most advanced antibody-drug conjugates (ADCs) after taking a look at the latest phase 2 data. |
By Gabrielle Masson As the U.S. cuts federal research funding and infrastructure, European countries are strategizing ways to attract top scientific talent, with the Netherlands government setting up a fund designed to do just that. |
By Gabrielle Masson "Eric Green, M.D. Ph.D., is no longer serving as director of NIH’s National Human Genome Research Institute," an NIH spokesperson told Fierce Biotech. |
By Gabrielle Masson Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 million IPO. |
By Darren Incorvaia,Zoey Becker About three months after leaving her post as the FDA’s principal deputy commissioner, Namandjé Bumpus, Ph.D., has found a new venture as a member of Recursion’s board of directors. |
By Nick Paul Taylor BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. Weeks after Eisai quietly made its choice, its liquid biopsy partner has revealed Bliss Biopharmaceutical plans to progress the program independently. |
By Dave Muoio The former physician-lawmaker was an influential player in congressional health policy during his 20-plus years in the House. The White House has not yet named its next choice for the position after pulling the nomination of Dave Weldon, M.D., last week. |
By Andrea Park,Eric Sagonowsky,Angus Liu This week on "The Top Line," we explore the potential impacts of this year's sizable patent cliff on the pharma industry at large. |
By Angus Liu AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho is acquiring antibody-drug conjugate expert Araris Biotech. WuXi AppTec expects sales to grow 10% to 15% in 2025. And more. |
Fierce podcasts Don’t miss an episode |
| Executive Editor Heather Landi and Senior Writer Paige Minemyer sit down to chat about the evolution of the Fierce 15 project and honorees. |
|
|---|
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
